Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.79B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$576M |
| 3 |
Microsoft
MSFT
|
+$546M |
| 4 |
iShares MSCI EAFE ETF
EFA
|
+$436M |
| 5 |
JPMorgan Chase
JPM
|
+$324M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$2.48B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.73B |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$765M |
| 4 |
Apple
AAPL
|
+$656M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$526M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 90.23% |
| 2 | Technology | 2.7% |
| 3 | Consumer Discretionary | 1.66% |
| 4 | Financials | 1.18% |
| 5 | Communication Services | 1.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
9051
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.87M
| $354K | ﹤0.01% |
8,497
-552
| -6% | -$21.9K |
|
9052
CALL
Kodak
KODK
$885M
| $353K | ﹤0.01% |
76,500
-63,700
| -45% | -$269K |
|
9053
PUT
Veru
VERU
$44.8M
| $353K | ﹤0.01% |
29,680
+4,500
| +18% | +$52.7K |
|
|
REVG
9054
DELISTED
REV Group
REVG
| $353K | ﹤0.01% |
26,610
+12,237
| +85% | +$140K |
|
|
NOAH
9055
Noah Holdings
NOAH
$589M
| $353K | ﹤0.01% |
25,039
-6,797
| -21% | -$106K |
|
9056
Nuveen ESG Emerging Markets Equity ETF
NUEM
$418M
| $352K | ﹤0.01% |
12,907
-24,591
| -66% | -$661K |
|
9057
Keros Therapeutics
KROS
$219M
| $352K | ﹤0.01% |
8,770
-17,783
| -67% | -$780K |
|
9058
PUT
Organogenesis Holdings
ORGO
$224M
| $352K | ﹤0.01% |
106,100
+800
| +0.8% | +$2.36K |
|
9059
PUT
Gladstone Investment Corp
GAIN
$654M
| $352K | ﹤0.01% |
27,000
-8,000
| -23% | -$105K |
|
9060
Global X Adaptive US Factor ETF
AUSF
$918M
| $352K | ﹤0.01% |
11,059
-24,569
| -69% | -$752K |
|
9061
CALL
Broadstone Net Lease
BNL
$4.32B
| $352K | ﹤0.01% |
22,800
-14,300
| -39% | -$229K |
|
9062
Companhia Siderúrgica Nacional
SID
$1.35B
| $352K | ﹤0.01% |
135,840
-152,871
| -53% | -$421K |
|
9063
CALL
Cyclerion Therapeutics
CYCN
$17.7M
| $352K | ﹤0.01% |
85,600
+81,320
| +1,900% | +$421K |
|
9064
Amplify BlueStar Israel Technology ETF
ITEQ
$114M
| $352K | ﹤0.01% |
+7,607
| New | +$345K |
|
9065
CALL
ADMA Biologics
ADMA
$2.09B
| $351K | ﹤0.01% |
95,200
+4,900
| +5% | +$18.2K |
|
9066
National Presto Industries
NPK
$1.09B
| $351K | ﹤0.01% |
4,797
+989
| +26% | +$72.7K |
|
9067
CALL
Core Laboratories
CLB
$567M
| $351K | ﹤0.01% |
15,100
-14,500
| -49% | -$328K |
|
|
XRLV
9068
DELISTED
Invesco S&P 500 ex-Rate Sensitive Low Volatility ETF
XRLV
| $351K | ﹤0.01% |
7,354
-8,290
| -53% | -$394K |
|
|
KREF
9069
KKR Real Estate Finance Trust
KREF
$488M
| $351K | ﹤0.01% |
28,841
-27,911
| -49% | -$314K |
|
9070
CALL
Cytek Biosciences
CTKB
$608M
| $351K | ﹤0.01% |
+41,100
| New | +$369K |
|
9071
Nicolet Bankshares
NIC
$3.6B
| $351K | ﹤0.01% |
5,167
-14,801
| -74% | -$938K |
|
9072
CALL
Compass
COMP
$8.42B
| $351K | ﹤0.01% |
100,200
-28,200
| -22% | -$92.5K |
|
|
SPPI
9073
CALL
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $351K | ﹤0.01% |
365,300
+72,800
| +25% | +$71.9K |
|
9074
CALL
Loews
L
$22.4B
| $350K | ﹤0.01% |
5,900
-10,300
| -64% | -$596K |
|
9075
Novartis
NVS
$292B
| $350K | ﹤0.01% |
3,470
-10,036
| -74% | -$1M |
|
Similar funds
Jeff Yass's Q2 2023 Portfolio in Review
As of Q2 2023, Jeff Yass held 13,811 positions worth $492B, up 4.6% from $470B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Jeff Yass's Q2 2023 filing shows 1,371 new, 4,862 increased, 5,559 reduced and 1,866 closed positions. Its largest new stake was State Street SPDR Portfolio Aggregate Bond ETF: 1,297,445 shares worth $32.9M. The largest sale was Invesco QQQ Trust, an estimated $2.48B.
By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 90% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q2 2023 buy was State Street SPDR Portfolio Aggregate Bond ETF: 1,297,445 shares worth $32.9M.
- Jeff Yass added most to NVIDIA in Q2 2023, an estimated $1.79B increase.
- Jeff Yass's biggest Q2 2023 reduction was Invesco QQQ Trust, cutting an estimated $2.48B.
- Jeff Yass fully exited Vanguard Intermediate-Term Corporate Bond ETF in Q2 2023, selling an estimated $45.5M.
- Jeff Yass's ten largest holdings make up 30% of its $492B portfolio in Q2 2023.
- Jeff Yass opened 1,371 new positions and closed 1,866 in Q2 2023.
- Jeff Yass's portfolio value rose 4.6% quarter-over-quarter to $492B.
Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.